$26.29
1.57%
Nasdaq, Jan 02, 10:02 pm CET
ISIN
US0042251084
Symbol
ACAD

ACADIA Pharmaceuticals Inc. Stock price

$26.29
+0.86 3.38% 1M
+5.05 23.78% 6M
-0.42 1.57% YTD
+7.63 40.89% 1Y
+10.37 65.14% 3Y
-26.52 50.22% 5Y
-8.33 24.06% 10Y
+16.44 166.90% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.42 1.57%
ISIN
US0042251084
Symbol
ACAD
Industry

Key metrics

Basic
Market capitalization
$4.4b
Enterprise Value
$3.6b
Net debt
positive
Cash
$847.0m
Shares outstanding
169.2m
Valuation (TTM | estimate)
P/E
17.2 | 31.9
P/S
4.2 | 4.0
EV/Sales
3.4 | 3.3
EV/FCF
16.7
P/B
4.9
Financial Health
Equity Ratio
61.7%
Return on Equity
30.9%
ROCE
24.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.0b | $1.1b
EBITDA
$265.6m | $120.9m
EBIT
$240.9m | $111.3m
Net Income
$261.2m | $139.3m
Free Cash Flow
$216.2m
Growth (TTM | estimate)
Revenue
121.8% | 15.2%
EBITDA
236.4% | 20.7%
EBIT
284.0% | 32.1%
Net Income
241.3% | -38.5%
Free Cash Flow
971.2%
Margin (TTM | estimate)
Gross
91.9%
EBITDA
25.4% | 11.0%
EBIT
23.0%
Net
24.9% | 12.6%
Free Cash Flow
20.7%
More
EPS
$1.5
FCF per Share
$1.3
Short interest
8.0%
Employees
654
Rev per Employee
$1.5m
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

18x Buy
69%
7x Hold
27%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
69%
Hold
27%
Sell
4%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,047 1,047
122% 122%
100%
- Direct Costs 85 85
9% 9%
8%
963 963
13% 13%
92%
- Selling and Administrative Expenses 523 523
128% 128%
50%
- Research and Development Expense 345 345
28% 28%
33%
266 266
236% 236%
25%
- Depreciation and Amortization 25 25
52% 52%
2%
EBIT (Operating Income) EBIT 241 241
284% 284%
23%
Net Profit 261 261
241% 241%
25%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
16 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadia's presenta...
Neutral
Business Wire
23 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver t...
Positive
Seeking Alpha
about one month ago
Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest.
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 654
Founded 1993
Website acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today